Brogan, David M. and Mossialos, Elias 
ORCID: 0000-0001-8664-9297
(2016)
Systems, not pills: the options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
Social Science & Medicine, 151.
pp. 167-172.
ISSN 0277-9536
Abstract
Over the past decade, there has been a growing recognition of the increasing growth of antibiotic resistant bacteria and a relative decline in the production of novel antibacterial therapies. The combination of these two forces poses a potentially grave threat to global health, in both developed and developing countries. Current market forces do not provide appropriate incentives to stimulate new antibiotic development, thus we propose a new incentive mechanism: the Options Market for Antibiotics. This mechanism, modelled on the principle of financial call options, allows payers to buy the right, in early stages of development, to purchase antibiotics at a discounted price if and when they ever make it to market approval. This paper demonstrates the effect of such a model on the expected Net Present Value of a typical antibacterial project. As part of an integrated strategy to confront the impending antibiotic crisis, the Options Market for Antibiotics may effectively stimulate corporate and public investment into antibiotic research and development
| Item Type: | Article |
|---|---|
| Official URL: | https://www.sciencedirect.com/science/journal/0277... |
| Additional Information: | © 2016 Elsevier |
| Divisions: | LSE Health |
| Subjects: | R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine |
| Date Deposited: | 12 Jan 2018 15:38 |
| Last Modified: | 12 Dec 2024 01:19 |
| URI: | http://eprints.lse.ac.uk/id/eprint/86432 |
Actions (login required)
 |
View Item |
